Zip, I wish we knew more about whatever strategy Edding will pursue once full approval is granted. My question regarding China is could a BP owner of AMRN play a key role in insuring Vascepa's success in China? One would think a BP has many more cards to play than AMRN has by itself. Stock analysts for AMRN do not even seem to comment on China. The potential could be huge but I doubt if Edding & AMRN are the right entities to unlock that potential. If a BP were involved who wanted to insure success in China they would have a comprehensive plan. Whatever the game plan for China with Edding & AMRN none of us are privy to. I only hope they have a plan.